Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2

Project: Other project

Project Details

StatusActive
Effective start/end date5/13/205/12/25

Funding

  • Eli Lilly & Company: $10,096.15